Cantourage Group SE: Record EBITDA and boom in the cannabis market!

Cantourage Group SE: Record EBITDA and boom in the cannabis market!

Berlin– A spectacular climb! Cantourage Group SE made an impressive comeback in the third quarter of 2024 with a bubbling EBITDA of 1.4 million euros, after recording a loss of 0.7 million euros in the same period last year. Sales shot up to 30.2 million euros in the first nine months of 2024, a huge jump compared to the 17 million euros of the previous year. These figures impressively demonstrate that Cantourage, Europe's leading listed cannabis company, is well on its way to profitable heights!

There are many CEOs, but Philip Schetter stands out with his vision: “In 2019, we started with sales of around 0.5 million euros and expect at least 40 million euros for 2024.” With partial legalization on April 1, 2024, the company was able to dramatically expand its processing capacity in Germany and Portugal to meet the exploding demand for cannabis products. In the third quarter of 2024 alone, Cantourage launched 16 new varieties and collaborated with six new cultivation partners worldwide!

Analysts are thrilled!

Things are getting colorful on the capital market: The analysis houses NuWays and Montega recently reaffirmed their buy recommendations for the Cantourage share, with sensational price targets of 10.00 euros and 11.00 euros. These positive analyzes reflect confidence in the company's future. “Medical cannabis is here to stay,” says Schetter optimistically. The new “Value” brand MEDICUS will be launched in November, with an attractive product portfolio that is primarily intended to appeal to patients with a limited budget.

A clear roadmap, a strong product portfolio and a tireless commitment to meeting patient needs – Cantourage has all the cards in hand to continue to be at the forefront of the dynamic European cannabis market!